蒲地蓝消炎口服液

Search documents
百亿王牌遇冷、集采围堵:济川药业遭遇业绩双降,创新药申请上市能否破局?|创新药观察
Hua Xia Shi Bao· 2025-07-10 03:42
本报(chinatimes.net.cn)记者于娜 北京报道 近日,济川药业公布的一个新动向引发投资者关注:其全资子公司收到国家药品监督管理局签发的1.1 类中药创新药小儿便通颗粒申报上市许可的《受理通知书》。 从百亿王牌蒲地蓝消炎口服液因说明书修订、调出地方医保等因素销量持续萎缩,到消化类主力产品雷 贝拉唑钠肠溶胶囊受集采冲击价格大幅下探,再到儿科大单品小儿豉翘清热颗粒增长动能减弱,济川药 业核心产品矩阵接连承压。2024 年营收、净利润同比双降,2025 年一季度业绩下滑幅度进一步扩大, 连续的业绩颓势让这家老牌药企面临前所未有的增长压力,曾经的行业光环逐渐褪色。 这款针对小儿便秘食积证的新药,在济川药业陷入业绩困境之际,被投资者寄予了突围的厚望,不过其 未来能否真正扛起"救市" 大旗,仍是未知数。 核心产品失势 作为国内"清热解毒、消化、儿科" 领域的中成药龙头,济川药业过往凭借蒲地蓝消炎口服液、小儿豉 翘清热颗粒、雷贝拉唑钠肠溶胶囊等拳头产品,取得了亮眼的成绩。从 2014 年至 2023 年,济川业绩增 速显著,净利润十年复合增速高达21.49% 。然而,市场风云变幻,如今的济川药业风光不再。 曾经 ...
济川药业: 湖北济川药业股份有限公司董事会关于曹飞要约收购事宜致全体股东的报告书
Zheng Quan Zhi Xing· 2025-07-04 16:12
湖北济川药业股份有限公司董事会 有关各方及联系方式 联系人:季文浩、吴卓 联系电话:021-68826021 董事会声明 一、本公司全体董事确信本报告书不存在任何虚假记载、误导性陈述或重大 遗漏,并对其内容的真实性、准确性、完整性承担法律责任。 关于 曹飞 要约收购事宜 致全体股东的报告书 董事会报告签署日期:二零二五年七月 三、本公司关联董事曹龙祥、曹飞、黄曲荣已回避对本报告书的审议表决, 本公司其他董事没有任何与本次要约收购相关的利益冲突。 释义 | 上市公司、公司、济川药业 | 指 湖北济川药业股份有限公司 | | --- | --- | | 收购人 指 | 曹飞 | | 济川控股 指 | 江苏济川控股集团有限公司 | | 西藏济川 指 | 西藏济川企业管理有限公司 | | 一致行动人 指 | 曹龙祥、济川控股、西藏济川 | | | 1,010 曹龙祥将其持有的济川控股 10.10%股权以 万元价格 | | 本次股权转让 指 | | | 转让给曹飞 | | | | 收购人曹飞以要约价格向除曹龙祥、济川控股及西藏济川 | | 本次收购、本次要约收购 | 指 以外的其他股东发出收购其所持有的上市公司全部无限 ...
济川药业(600566):儿科中药龙头,BD赋能长期发展
Changjiang Securities· 2025-06-22 04:54
[Table_Title] 儿科中药龙头,BD 赋能长期发展 公司研究丨深度报告丨济川药业(600566.SH) %% %% %% %% research.95579.com 1 丨证券研究报告丨 报告要点 [Table_Summary] 公司专注于儿科、呼吸、消化、妇产及其它领域药品的生产和销售,主要产品为蒲地蓝消炎 口服液、小儿豉翘清热颗粒等。除药品业务外,公司子公司蒲地蓝日化主要从事蒲地蓝牙膏 等日化产品业务,康煦源主要从事保健品业务。同时公司加快推进产业转型升级,2021 年起 公司持续推进优质产品 BD 引入,以商业拓展赋能外延式扩张,为公司长期发展奠定基础。 分析师及联系人 [Table_Author] 彭英骐 张楠 SAC:S0490524030005 SAC:S0490524070006 SFC:BUZ392 请阅读最后评级说明和重要声明 2 / 20 %% %% %% %% research.95579.com 2 济川药业(600566.SH) cjzqdt11111 [Table_Title2] 儿科中药龙头,BD 赋能长期发展 [Table_Summary2] 儿科中药龙头,长期稳健发 ...
济川药业实控人或将变为父子 股权转让触发全面要约收购
Jing Ji Guan Cha Wang· 2025-06-17 03:59
Group 1 - The core point of the news is the announcement of a family internal equity structure adjustment at Jichuan Pharmaceutical, which triggers a mandatory general offer for the company's shares by Cao Fei, the son of the actual controller, Cao Longxiang [1][2] - On June 11, Cao Longxiang transferred 10.10% of his shares in Jichuan Holdings to Cao Fei for 10.1 million yuan, resulting in Cao Fei holding 60% of Jichuan Holdings and indirectly controlling 5.17 billion shares of Jichuan Pharmaceutical, which is 56.07% of the total share capital [1] - The general offer price is set at 26.93 yuan per share, requiring a maximum total funding of 9.448 billion yuan, with the offer period lasting from June 18, 2025, to July 17, 2025 [2] Group 2 - Jichuan Pharmaceutical's major shareholder structure remains unchanged after the transfer, with Jichuan Holdings holding 4.17 billion shares, accounting for 45.22% of the total share capital, and the combined holdings of the controlling shareholder and concerted parties reaching 61.15% [1] - The company reported a revenue of 1.525 billion yuan in the first quarter of 2025, a year-on-year decrease of 36.51%, and a net profit attributable to shareholders of 440 million yuan, down 47.91% year-on-year [3] - The decline in revenue is attributed to two main factors: a high base in the first quarter of 2024 and the impact of centralized procurement on the main product, Rabeprazole Sodium Enteric-coated Capsules [3]
父子股权调整触发要约收购,曹飞欲斥资94亿收购济川药业3.5亿股
Huan Qiu Lao Hu Cai Jing· 2025-06-16 13:31
Group 1 - The actual controller of Jichuan Pharmaceutical, Cao Longxiang, is transferring shares to his son, Cao Fei, which triggers a mandatory tender offer for the company [1][2] - Cao Fei will acquire 351 million shares, representing 38.06% of the total issued shares, with a maximum transaction value of 9.448 billion yuan [1][2] - Following the share transfer, Cao Fei's stake in Jichuan Holdings will increase to 60%, allowing him to indirectly control 517 million shares of Jichuan Pharmaceutical, exceeding the 30% threshold for a mandatory tender offer [2] Group 2 - Jichuan Pharmaceutical is facing significant pressure, with revenue and net profit declining for four consecutive quarters due to price cuts from centralized procurement [4] - In 2024, the company expects to achieve revenue of 8.017 billion yuan, a year-on-year decrease of 16.96%, and a net profit of 2.532 billion yuan, down 10.32% [4] - The company's sales expenses are high at 2.954 billion yuan, accounting for 36.85% of total revenue, while R&D expenses are only 445 million yuan, representing 5.55% of total revenue [4]
中药行业洗牌:独家品种光环渐褪,要“瘦身”还是“增肌”?
2 1 Shi Ji Jing Ji Bao Dao· 2025-05-15 09:11
21世纪经济报道记者 李佳英 广州报道 "有效需求不足、行业加速变革、行业政策变化及市场竞争激烈",白云山年报中的这段表述,或许道出 了整个中药行业的集体焦虑。 21世纪经济报道记者梳理中药企业2024年以及2025年第一季度业绩表现,发现中药行业格局呈现出分化 态势,部分企业凭借品牌优势、产品创新及市场拓展实现了稳健增长,而部分企业则面临营收下滑、利 润承压等问题。 在2024年,白云山营收规模虽居首,但同比下滑0.69%,反映出传统中药巨头增长乏力;步长制药因核 心产品收入下滑及销售费用高企,亏损7.02亿元。与此同时,达仁堂净利润同比大增128.68%,东阿阿 胶净利润增长25.57%,成为"增利黑马"。 进入2025年第一季度,头部企业延续增长态势,而尾部企业仍面临压力。 曾被视为"现金奶牛"的独家品种战略,在医保目录调整与集采扩围的双重夹击下遭遇挑战。面对行业变 革,中药企业转型路径呈现差异。例如,达仁堂剥离商业板块,华润三九通过并购天士力补强产业链, 马应龙从痔疮药延伸至肛肠医院,片仔癀则依托国家保密配方推进林麝养殖与海外市场拓展。 在集采与成本压力下,中药企业如何平衡价格与市场份额、筑起品牌护城 ...
济川药业:业绩短期承压,分红表现超预期-20250427
SINOLINK SECURITIES· 2025-04-27 06:23
Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [5][13]. Core Insights - The company reported a revenue of 8.017 billion RMB in 2024, a decrease of 17% year-on-year, and a net profit attributable to shareholders of 2.532 billion RMB, down 10% year-on-year [2]. - In Q1 2025, the company achieved a revenue of 1.525 billion RMB, reflecting a 37% decline year-on-year, with a net profit of 440 million RMB, down 48% year-on-year [2]. - The company's core products faced pressure due to high base effects and centralized procurement policies, particularly impacting key products like Pudilan and pediatric medications [3]. - The company has made progress in product introductions, securing four new product agreements, which are expected to support long-term growth [3]. - The company has a strong cash position with over 12.5 billion RMB in cash and financial assets, and it plans to distribute a cash dividend of 2.09 RMB per share, totaling approximately 1.922 billion RMB, which is 75.93% of the net profit for 2024 [4]. Financial Forecasts - Revenue forecasts for 2025 and 2026 have been revised down to 7.421 billion RMB and 8.139 billion RMB, respectively, with net profit estimates adjusted to 2.263 billion RMB and 2.557 billion RMB [5]. - The expected earnings per share (EPS) for 2025, 2026, and 2027 are projected to be 2.456 RMB, 2.774 RMB, and 3.126 RMB, respectively, with corresponding price-to-earnings (P/E) ratios of 10, 9, and 8 times [5].
济川药业(600566):业绩短期承压,分红表现超预期
SINOLINK SECURITIES· 2025-04-27 05:20
Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [5][13]. Core Views - The company reported a revenue of 8.017 billion yuan in 2024, a decrease of 17% year-on-year, and a net profit attributable to shareholders of 2.532 billion yuan, down 10% year-on-year [2]. - The first quarter of 2025 showed a significant decline in performance, with revenue of 1.525 billion yuan, a 37% decrease year-on-year, and a net profit of 440 million yuan, down 48% year-on-year [2]. - The company is expected to see easing pressure from high revenue bases starting from Q2 2025, which may positively impact its core products [3]. Summary by Sections Performance Overview - In 2024, the company achieved a revenue of 8.017 billion yuan, a decline of 17% year-on-year, and a net profit of 2.532 billion yuan, down 10% year-on-year. The first quarter of 2025 saw revenue drop to 1.525 billion yuan, a 37% decrease year-on-year, with a net profit of 440 million yuan, down 48% year-on-year [2]. Operational Analysis - The company's core products faced pressure due to high revenue bases from the previous year and the impact of centralized procurement policies. Revenue from heat-clearing and detoxifying products was approximately 2.69 billion yuan, down 20% year-on-year, while pediatric products generated about 2.25 billion yuan, down 18% year-on-year [3]. - The company has successfully introduced four new products or partnerships in 2024, including a new drug in the respiratory field and a new pediatric drug in the ENT field [3]. Cash Flow and Dividends - As of Q1 2025, the company had over 12.5 billion yuan in cash and cash equivalents, indicating a strong cash position. The proposed cash dividend for 2024 is 2.09 yuan per share, totaling approximately 1.922 billion yuan, which represents 75.93% of the net profit attributable to shareholders for 2024 [4]. Profit Forecast and Valuation - The revenue forecasts for 2025 and 2026 have been revised down to 7.421 billion yuan and 8.139 billion yuan, respectively. The net profit forecasts for the same years have also been adjusted to 2.263 billion yuan and 2.557 billion yuan, respectively. The expected EPS for 2025-2027 is 2.46, 2.77, and 3.13 yuan, with corresponding PE ratios of 10, 9, and 8 times [5].